Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jun 25;8(12):3311-3313.
doi: 10.1182/bloodadvances.2024013146.

CAR T-cell expansion: harmful or helpful?

Anath C Lionel  1 , Sattva S Neelapu  1
Affiliations
Comment

CAR T-cell expansion: harmful or helpful?

Anath C Lionel et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.S.N. received research support from Kite/Gilead, Bristol Myers Squibb (BMS), Allogene, Precision Biosciences, Adicet Bio, Sana Biotechnology, and Cargo Therapeutics; served as advisory board member/consultant for Kite/Gilead, Merck, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, bluebird bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, MorphoSys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda, Synthekine, Carsgen, Appia Bio, and GlaxoSmithKline; has stock options from Longbow Immunotherapy, Inc; and has intellectual property related to cell therapy. A.C.L. declares no competing financial interests.

Comment on

  • CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
    Hamilton MP, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, Ehlinger Z, Syal S, Good Z, Sworder B, Schroers-Martin J, Lu Y, Muffly L, Negrin RS, Arai S, Lowsky R, Meyer E, Rezvani AR, Shizuru J, Weng WK, Shiraz P, Sidana S, Bharadwaj S, Smith M, Dahiya S, Sahaf B, Kurtz DM, Mackall CL, Tibshirani R, Alizadeh AA, Frank MJ, Miklos DB. Hamilton MP, et al. Blood Adv. 2024 Jun 25;8(12):3314-3326. doi: 10.1182/bloodadvances.2024012637. Blood Adv. 2024. PMID: 38498731 Free PMC article.

References

    1. Hamilton MP, Craig E, Gentille Sanchez C, et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 2024;8(12):3314–3326. - PubMed
    1. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. - PMC - PubMed
    1. Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–2606. - PMC - PubMed
    1. Strati P, Gregory T, Majhail NS, Jain N. Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review. JCO Oncol Pract. 2023;19(9):706–713. - PubMed
    1. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicenter, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. - PubMed

MeSH terms

Substances